Werbung
Werbung

CLGN

CLGN logo

CollPlant Biotechnologies Ltd Ordinary Shares

1.47
USD
Gesponsert
+0.03
+2.15%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

1.47

0.00
-0.07%

CLGN Ergebnisberichte

Positives Überraschungsverhältnis

CLGN übertreffen die 3 der letzten 25Schätzungen.

12%

Nächster Bericht

Datum des nächsten Berichts
24. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.55M
/
-$0.12
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+1919.47%
/
-55.56%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+848.16%
/
-64.71%

CollPlant Biotechnologies Ltd Ordinary Shares earnings per share and revenue

On 26. Nov. 2025, CLGN reported earnings of -0.27 USD per share (EPS) for Q3 25, missing the estimate of 0.15 USD, resulting in a -270.78% surprise. Revenue reached 77.00 tausend, compared to an expected 4.94 million, with a -98.44% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 1.55 million USD, implying an decrease of -55.56% EPS, and increase of 1919.47% in Revenue from the last quarter.
FAQ
For Q3 2025, CollPlant Biotechnologies Ltd Ordinary Shares reported EPS of -$0.27, missing estimates by -270.78%, and revenue of $77.00K, -98.44% below expectations.
The stock price moved down -0.45%, changed from $2.24 before the earnings release to $2.23 the day after.
The next earning report is scheduled for 24. März 2026.
Based on 4 analysts, CollPlant Biotechnologies Ltd Ordinary Shares is expected to report EPS of -$0.12 and revenue of $1.55M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung